Agile Therapeutics Inc (AGRX) Directors and Executive Officers

Officers & Directors

SHARON BARBARI
Director

JOSEPHINE TORRENTE
Director

JOHN HUBBARD, Ph.D.
Director

SETH H.Z. FISCHER
Director

SCOTT M. COIANTE
Chief Financial Officer (Principal Accounting Officer)

ALFRED ALTOMARI
Chief Executive Officer and Director (Principal Executive Officer)

SANDRA CARSON, M.D., FACOG
Director ,

Agile Therapeutics Inc currently has 19 employees.

News about Agile Therapeutics Inc Key Personnel

Agile Therapeutics Inc Bolsters Financial Position, Eliminating Debt and Poised for Growth

Agile Therapeutics Inc: Eliminating Debt and Focused on Business Plan Execution
Agile Therapeutics Inc, a pharmaceutical company specializing in women’s healthcare, has announced the successful completion of its debt repayment to Perceptive Advisors. This significant development has left the company with a debt-free balance sheet, providing a strong foundation for future growth and securing investor confidence.
Having struggled with a heavy debt load in recent years, Agile Therapeutics has made remarkable progress in improving its financial position. By eliminating its remaining debt to Perceptive Advisors, the company can now focus its resources and attention on executing its business plan and pur...

Agile Therapeutics: Pioneering Women's Healthcare with Innovative Contraceptives and Nasdaq Listing Compliance Extension

Agile Therapeutics Granted Extension by Nasdaq Hearings Panel and Provides Performance Update
Agile Therapeutics, a leading women s healthcare company focusing on the development and commercialization of innovative healthcare products, recently announced that it has been granted an extension by the Nasdaq Hearings Panel to regain compliance with the Stockholders Equity Continued Listing Requirement. The extension allows the company to continue trading on the Nasdaq Global Market until March 25, 2024. Agile Therapeutics also provided a performance update, highlighting significant achievements and future prospects.
The decision from the Nasdaq Hearings Panel to grant Agile Therapeutics an extension re...